Novartis Halted Eight CAR T-Cell Trials After Deaths
The manufacturer suspended studies involving autoimmune diseases after three participants died from a severe immune complication.
Updated on Sept. 28, 2026 in Arthritis
Live Poll
Would you participate in a medical trial if it carried a risk of fatal side effects?
On August 24, 2026, Novartis suspended eight clinical trials investigating the CAR T-cell therapy rapcabtagene autoleucel. The decision followed the deaths of three trial participants diagnosed with immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH).
Why it matters
The halt reflects the high safety stakes associated with advanced cell therapies, which are being investigated for difficult-to-treat autoimmune conditions like lupus, rheumatoid arthritis, and multiple sclerosis. It underscores the ongoing challenge of balancing the potential for deep remission against the risks of hyper-inflammatory immune responses.
A 2025 review of 145 patients receiving CAR T-cell therapies reported a 70% remission rate based on DORIS criteria. Current safety investigations remain ongoing following the reported deaths during the 2026 trial period.
The players
Novartis
A pharmaceutical company that develops advanced therapies, including cell and gene treatments for complex chronic and autoimmune conditions.
The details
Rapcabtagene autoleucel functions by reprogramming a patient's own T-cells to target specific immune system cells involved in autoimmune pathology. However, this process can trigger a severe, life-threatening inflammatory cascade known as HLH, which occurs when activated immune cells cause organ damage. Standard management for this complication involves aggressive high-dose steroids and chemotherapy agents to suppress the overactive immune system.
Timeline
2025: A review article regarding CAR T-cell therapy efficacy was published.
August 24, 2026: Novartis halted eight clinical trials.
2026: Data regarding refractory systemic sclerosis was presented at the EULAR 2026 Congress.
Health Landscape
The suspension of rapcabtagene autoleucel trials marks a stark contrast to the positive efficacy data presented at the EULAR 2026 Congress. This pause highlights the gap between achieving successful disease remission in research settings and managing complex systemic safety risks in practice.
Patients currently participating in or considering clinical trials for autoimmune therapies should ask their physician about the specific safety monitoring protocols in place. It is important to discuss potential inflammatory side effects and how they are identified during the informed consent process.
The takeaway
The halt of these trials serves as a reminder that emerging cell therapies carry distinct, serious immunological risks alongside their potential for benefit. Patients should prioritize clear conversations with their rheumatologist regarding the balance of safety and efficacy in advanced treatment options.
Further reading
Learn more about the latest research and standard treatment approaches at Arthritis.
Source note: This article includes information reported by Healio.
Live Poll
Would you participate in a medical trial if it carried a risk of fatal side effects?
